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ABSTRACT Estimating epidemiological cutoff endpoints (ECVs/ECOFFS) may be hin-
dered by the overlap of MICs for mutant and nonmutant strains (strains harboring
or not harboring mutations, respectively). Posaconazole MIC distributions for the
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Aspergillus fumigatus species complex were collected from 26 laboratories (in Austra-
lia, Canada, Europe, India, South and North America, and Taiwan) and published
studies. Distributions that fulfilled CLSI criteria were pooled and ECVs were esti-
mated. The sensitivity of three ECV analytical techniques (the ECOFFinder, normal-
ized resistance interpretation [NRI], derivatization methods) to the inclusion of MICs
for mutants was examined for three susceptibility testing methods (the CLSI, EU-
CAST, and Etest methods). The totals of posaconazole MICs for nonmutant isolates
(isolates with no known cyp51A mutations) and mutant A. fumigatus isolates were as
follows: by the CLSI method, 2,223 and 274, respectively; by the EUCAST method,
556 and 52, respectively; and by Etest, 1,365 and 29, respectively. MICs for 381 iso-
lates with unknown mutational status were also evaluated with the Sensititre Yeast-
One system (SYO). We observed an overlap in posaconazole MICs among nonmu-
tants and cyp51A mutants. At the commonly chosen percentage of the modeled
wild-type population (97.5%), almost all ECVs remained the same when the MICs for
nonmutant and mutant distributions were merged: ECOFFinder ECVs, 0.5 g/ml for
the CLSI method and 0.25 g/ml for the EUCAST method and Etest; NRI ECVs, 0.5
g/ml for all three methods. However, the ECOFFinder ECV for 95% of the nonmu-
tant population by the CLSI method was 0.25 g/ml. The tentative ECOFFinder ECV
with SYO was 0.06 g/ml (data from 3/8 laboratories). Derivatization ECVs with or
without mutant inclusion were either 0.25 g/ml (CLSI, EUCAST, Etest) or 0.06 g/ml
(SYO). It appears that ECV analytical techniques may not be vulnerable to overlap
between presumptive wild-type isolates and cyp51A mutants when up to 11.6% of
the estimated wild-type population includes mutants.
KEYWORDS Aspergillus fumigatus, CLSI ECVs, ECVs, EUCAST ECVs, Etest, SYO, cyp51A
mutants, posaconazole, triazole resistance, wild type
Among the species of filamentous fungi (molds), Aspergillus fumigatus is the mostprevalent species causing severe infections; the attributable mortality rate for
aspergillosis is as high as 47%, which is dependent on both the patient population and
patient age (1–4). Although A. fumigatus frequently affects the lungs and sinuses,
Aspergillus can infect other organs, including the central nervous system and the heart
(4, 5). Posaconazole is recommended as salvage therapy in patients failing first-line
treatment for invasive aspergillosis, as well as empirical, prophylactic, and/or adjunctive
therapies (5). While routine antifungal susceptibility testing (determination of MICs) is
not recommended during initial aspergillosis therapy, susceptibility testing has an
important role in identifying potentially resistant isolates, e.g., isolates from patients
failing therapy (5). Ideally, MICs ought to be obtained using a reliable antifungal
susceptibility assay for which breakpoints (BPs) and/or epidemiological cutoff values
(ECVs/ECOFFs) have been established (e.g., by susceptibility testing reference methods).
Method-dependent and species-specific ECVs are based on MIC/minimal effective
concentration (MEC) data derived from multiple laboratories, and establishment of
ECVs is also the first step for establishing breakpoints (6–9). ECVs are particularly
important when limited clinical data have precluded the development of BPs, which is
the case for many fungal species.
Two reference methods are available for testing the susceptibilities of molds to
posaconazole and other agents: the M38 method by the Clinical and Laboratory
Standards Institute (CLSI) and a similar microdilution method by the Antifungal Sub-
committee of the European Committee on Antimicrobial Susceptibility Testing (EU-
CAST) (10, 11) (http://www.eucast.org/ast_of_fungi/). EUCAST has listed a susceptible
BP (0.12 g/ml) as well as an ECV (ECOFF, 0.25 g/ml) for posaconazole and A.
fumigatus. The CLSI has not listed or approved interpretive endpoints for this species/
agent (8). A perception has emerged that the suggested posaconazole ECV (either 0.25
or 0.5 g/ml), which was based on CLSI data from four laboratories, is not suitable in
separating nonmutant from mutant isolates, e.g., those harboring cyp51A gene muta-
tions (27). An overlap between MICs for presumptive wild-type (WT) and mutant
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isolates has recently been documented by EUCAST (http://www.eucast.org/ast_of
_fungi/). Other interpretive endpoints (susceptible BP, 0.06 g/ml; ECV, 0.12 g/ml;
pharmacokinetic/pharmacodynamic [PD] breakpoint, 0.25 g/ml) have been proposed
for posaconazole and A. fumigatus using CLSI MICs, PD data, genetic mutations, animal
studies, or a combination of these parameters (12, 13).
Among the commercial antifungal susceptibility testing methods (14–16), the broth
colorimetric microdilution Sensititre YeastOne (SYO; Trek Diagnostic System, Cleveland,
OH) and especially the agar diffusion Etest (bioMérieux, Marcy l’Etoile, France) methods
have been evaluated for testing the susceptibilities of molds to posaconazole and other
agents (17–19). More recently, these studies have incorporated mutant A. fumigatus
strains (20–22). However, the testing parameters provided by the manufacturers are
more specific for Candida spp., and both package inserts list CLSI endpoints as
interpretive categories (10, 14, 16). Therefore, there is a need to further investigate
these issues by evaluating available posaconazole MICs for the A. fumigatus species
complex (SC) by these four susceptibility testing methods.
The objectives of the present study were (i) to pool the MICs for isolates of the A.
fumigatus SC that were obtained by four antifungal susceptibility testing assays (CLSI,
EUCAST, Etest, and SYO) and collected from 26 independent worldwide laboratories
and published studies (12, 20, 23, 24); (ii) to define method-dependent posaconazole
MIC distributions for nonmutant and mutant isolates by each susceptibility testing
method; (iii) to examine the suitability of these distributions for each method-
dependent ECV setting, including the evaluation of interlaboratory modal agreement;
(iv) to evaluate the overlap of MICs for mutant and nonmutant isolates; and (v) to
compare the sensitivity of three ECV analytical approaches (the ECOFFinder, normalized
resistance interpretation [NRI], and derivatization methods) (9, 25, 26) to the inclusion
of MICs for mutant isolates in each nonmutant posaconazole MIC distribution to be
analyzed when the distribution comprised 100 MICs that originated in 3 to 15
laboratories. The CLSI MIC distributions for two Aspergillus cryptic species (55 A. lentulus
and 21 A. udagawae isolates) collected from three laboratories were also provided. The
data for mutants from the participant laboratories originated mostly from European
laboratories, in addition to data from Australia, Argentina, and Thailand; by adding data
from a published study (24), we also collected data from China.
RESULTS AND DISCUSSION
The recommended major predictor of the clinical response to antimicrobial therapy
is the method- and species-dependent BP. In lieu of BPs for mold testing, the CLSI has
approved ECVs for various triazoles and species of Aspergillus but not for posaconazole
and A. fumigatus (8, 27). Etest ECVs are available for amphotericin B and the echino-
candins and Aspergillus isolates (28), but Etest or SYO ECVs for Aspergillus spp. and the
triazoles have not been proposed. Therefore, we collected the available CLSI, EUCAST,
Etest, and SYO posaconazole MICs from 26 laboratories and reevaluated the definition
of method-dependent posaconazole ECVs for A. fumigatus SC isolates using the CLSI
and EUCAST MIC distributions for nonmutant and mutant isolates that originated in 15
and 6 laboratories, respectively, including published studies (12, 23, 24). Using the same
methods, we proposed posaconazole Etest and SYO ECVs for A. fumigatus SC isolates
based on the Etest MIC distributions for nonmutant and mutant isolates and SYO data
for nondifferentiated isolates from 8 and 3 laboratories, respectively. The total number
of MIC values for mutants determined by the CLSI, EUCAST, and Etest methods
originating from published studies versus participant laboratories were as follows: 227
(82.8%) versus 47 (17.2%), respectively, for the CLSI method; 3 (6%) versus 49 (94%),
respectively, for the EUCAST method (12, 23, 24); and 5 (17%) versus 24 (83%),
respectively, for the Etest method (20) (Table 1). In addition, our ECVs were estimated
by the ECOFFinder, NRI, and derivatization procedures to compare their sensitivity to
the presence of MICs for mutants within each mixed MIC distribution of nonmutant and
mutant isolates. We also examined the overlap between our posaconazole MICs for
nonmutant versus mutant isolates of the A. fumigatus SC using a substantial number of
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MICs for mutants (n  355) determined by three of the four susceptibility testing
methods (CLSI, EUCAST, and Etest). To our knowledge, there are no other species/agent
combinations with such a large number of MIC data for mutants and nonmutants to
test the effectiveness of the different analytical methods.
The criteria for ECV definition have recently been postulated by the CLSI and
summarized elsewhere (6, 7, 9). Those criteria were met for the minimum of 100
MIC/MEC values in a pool of data points for ECV definition analysis (Table 2); the
minimum number of isolates for an individual nonmutant distribution by the three
methods was 24, higher than the acceptable 5 (CLSI) or 15 (EUCAST) (EUCAST Standard
Operating Procedure [EUCAST SOP 10.0; http://www.eucast.org/documents/sops/]).
The maximum number of isolates in individual distributions before pooling was 449, or
20% of the total 2,223 nonmutant data points, by the CLSI method (Table 2). Thus, there
was no need to weigh the distributions used for the analysis, because none of the
single distributions included 50% of the entire nonmutant population evaluated by
three of the four methods (the smallest number of isolates in the pool was 25, or 1%);
the exception was a single distribution by the SYO method that included 56% of the
data points used to define the tentative SYO ECV.
Among the 2,223 nonmutant isolates for which CLSI MICs were available, 58% (1,289
data points) were A. fumigatus sensu stricto and 42% were A. fumigatus SC isolates (e.g.,
identification confirmed by either molecular methods [e.g., matrix-assisted laser de-
sorption ionization–time of flight {MALDI-TOF} mass spectrometry and -tubulin and
calmodulin sequencing] or morphological methods) (29, 30). After pooling of the MICs
for nonmutants, there was no observable difference in the MIC distributions between
A. fumigatus SC and A. fumigatus sensu stricto strains. All mutant isolates were A.
fumigatus sensu stricto (Table 2). Of the four distributions evaluated in a prior study (27),
TABLE 1 Posaconazole MICs for 355 Aspergillus fumigatus sensu stricto cyp51A mutants
determined by three susceptibility testing methodsa
Mutationb Method
No. of isolates with MIC (g/ml) of:
0.016 0.03 0.06 0.125 0.25c 0.5 1 2 4 8 >16 Total
TR34/L98H CLSI 1 1 0 3 53 109 30 8 1 0 206
EUCAST 4 10 5 4 1 24
Etest 1 2 5 1 4 13
G54E/R/V/W CLSI 1 6 2 5 7 21
EUCAST 1 1 4 6
Etest 1 1 3 5
TR46/Y121F CLSI 1 7 1 9
EUCAST 1 9 10
Etest 1 1
M220I/R/T/V/K CLSI 1 2 3 4 1 2 13
EUCAST 1 1 1 3
Etest 1 1 1 1 4
G448S CLSI 1 5 6
EUCAST 1 4 5
Etest 1 1 3 5
G138C CLSI 1 2 1 1 5
EUCAST 1 1
Etest 0
Otherb CLSI 2 1 1 1 4 3 1 1 14
EUCAST 1 1 1 3
Etest 1 1
aMICs were determined by the CLSI M38-A, EUCAST, and Etest methods (10, 11, 16).
bOther includes F219I, 1301T, M172, P216L, Y431, TR34/L98H  M172V, and unknown (most commonly,
G54E and M220I); mutant data are from the study laboratories and previous studies (12, 20, 23, 24).
cThe postulated ECV is 0.25 g/ml.
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the largest was excluded due to an aberrantly low mode (1,152 data points). The
analysis of modal variability indicated that of the CLSI posaconazole MICs collected
from 18 independent laboratories, 13 had acceptable distributions. These data were
pooled with data from two previous studies for further analyses (12, 23); the modes
from the 15 laboratories ranged from 0.06 to 0.12 g/ml, an acceptable distribution
pool for ECV definition according to the CLSI criteria for this purpose (7, 8). The
excluded distributions from five laboratories were truncated, had no clear mode, or had
modes at least 2 dilutions either below (0.016 g/ml) or above (1 g/ml) the global
mode of 0.12 g/ml (6, 7). Similar screening has been performed for other CLSI ECVs
with comparable exclusion rates; e.g., 4 of 13 distributions were not pooled for the
definition of the CLSI ECV for Candida albicans versus fluconazole due to aberrant
distributions (6). The mode for the merged 274 A. fumigatus sensu stricto mutants (47
versus 227 isolates from the study laboratories and previous studies, respectively) was
higher, 0.5 g/ml (12, 23). CLSI posaconazole MICs for the 55 A. lentulus isolates ranged
from 0.12 to 4 g/ml (mode, 0.5 g/ml), and those for the 21 A. udagawae isolates
ranged from 0.25 to 1 g/ml (mode, 0.25 g/ml) (29, 30). Responses to the survey
indicated that the CLSI MICs were determined according to the M38-A2 method testing
conditions (described below). Overall, MICs for the quality control (QC) isolates were
within expected MIC limits (10); the exceptions were that 4.5% of posaconazole MICs for
the QC isolates Candida krusei ATCC 6258 and C. parapsilosis were 1 dilution lower than
the expected limits (0.06 to 1 g/ml and 0.03 to 0.25 g/ml, respectively). It is
noteworthy that CLSI has lowered the posaconazole MIC limit for the QC isolate C.
parapsilosis ATCC 22019 from 0.06 to 0.25 g/ml to 0.03 to 0.25 g/ml (CLSI, minutes
of the annual meeting, 8 January 2011, Orlando, FL).
EUCAST posaconazole MICs for 556 nonmutant and 52 mutant A. fumigatus sensu
stricto isolates from five independent laboratories were pooled and merged with
published data (24) (Table 2). The modes for the six individual distributions were
comparable, with an overall mode of 0.12 g/ml, or the same as that for the CLSI data.
Therefore, all collected distributions were included for further ECV analysis. The MIC
ranges for nonmutant and mutant isolates were slightly more discriminatory by the
TABLE 2 Pooled posaconazole MIC distributions for Aspergillus fumigatus SC isolates from
between 3 and 15 laboratories determined by four susceptibility testing methodsa
Method and type
of MIC
distributionb
No. of
labs
No. of
isolates
No. of isolates with MIC (g/ml) ofc:
<0.016 0.03 0.06 0.12 0.25 0.5 1 2 4 8 >16
CLSI
Nonmutants 15 2,223 39 332 597 762 365 89 26 5 2 2 4
Mutants 6 274 1 3 3 5 57 123 51 16 3 1 11
Merged data 15 2,497 40 335 600 767 422 212 77 21 5 3 15
EUCAST
Nonmutants 6 556 7 60 195 214 73 7
Mutants 6 52 1 1 10 12 16 5 1 0 6
Merged data 6 608 7 61 195 215 83 19 16 5 1 0 6
Etest
Nonmutants 8 1,365 56 105 529 572 75 14 5 6 1 0 2
Mutants 5 29 2 2 6 8 2 1 8
Merged data 8 1,394 56 105 529 572 77 16 11 14 3 1 10
SYO 3 381 134 157 45 20 11 7 4 2 0 0 1
aPosaconazole MICs were obtained by following both the CLSI and EUCAST reference microdilution methods
as well as the commercial Etest agar diffusion and SYO broth dilution colorimetric assays (10, 11, 13, 15, 16).
bWT, pooled posaconazole MICs for nonmutants; Mutants, pooled posaconazole MICs for isolates harboring
cyp51A gene mutations; Merged data, aggregated posaconazole MIC distributions for nonmutants and
mutants. Among the WT isolates, 58%, 33%, and 29% of the MICs were for A. fumigatus sensu stricto isolates
by the CLSI, Etest, and SYO methods, respectively. All EUCAST data were for A. fumigatus sensu stricto
isolates.
cThe highest number in each row (showing the most frequently obtained MIC or the mode) is indicated in
boldface.
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EUCAST method than by the CLSI method (0.016 to 0.5 g/ml for nonmutants versus
0.03 to 16 g/ml for mutants). The EUCAST method seemed to provide a better split
of the MICs for nonmutants and mutants, with a mode for the mutants of 1 g/ml
versus a CLSI mode of 0.5 g/ml. There was a noticeable difference between the
EUCAST and CLSI wild-type distributions: the two methods had similar means (log2,
3.94 versus 3.86, respectively) but the EUCAST method had a lower standard
deviation (SD) (log2, 0.897 versus 1.124, respectively) (ECOFFinder analysis). These
differences may be due to the smaller number of laboratories and EUCAST MICs in the
total.
Etest posaconazole MICs for 1,394 isolates of A. fumigatus SC (a total of 450 [33%]
of the 1,365 nonmutant isolates and the 29 mutants were A. fumigatus sensu stricto)
from 7 of 9 independent laboratories were acceptable and were merged with those of
a previous study (20) (Table 2). The two excluded distributions were either truncated or
had an unacceptable low mode (0.03 g/ml) 2 dilutions below the global mode of 0.12
g/ml and the same mode as that for both reference methods. The responses to the
survey from each of the nine laboratories revealed that Etest posaconazole MICs were
obtained by using solidified RPMI medium supplemented with 2% dextrose and that
MICs were determined after 24 h but mostly at 48 h of incubation (when there was an
absence of growth in the inhibition ellipse). Again, MICs were outside (4.6%, 1 dilution
lower values) the expected limits for the QC isolates C. parapsilosis ATCC 22019 (0.03 to
0.25 g/ml) and C. krusei ATCC 6258 (0.12 to 0.25 g/ml) per the manufacturer’s table
(16). There was also a difference between the Etest and CLSI nonmutant distributions:
the former method had a higher geometric mean (log2, 4.042 versus 3.86, respec-
tively) and a lower SD (log2, 0.779 versus 1.124, respectively). These discrepancies could
be due to the different susceptibility testing methodologies (broth microdilution versus
agar gradient diffusion).
Only 3 of the 8 submitted single SYO posaconazole MIC distributions for 381 A.
fumigatus SC isolates (29% [110 data points], A. fumigatus sensu stricto) were pooled for
further ECV analyses. The global modal MIC was 0.03 g/ml, or much lower than that
obtained by the other three susceptibility testing methods (Table 2). The five excluded
distributions were mostly truncated or had no obvious mode. Although SYO posacona-
zole data for mutant isolates of A. fumigatus have been documented (21, 22), the
nonmutant MIC distributions were not comparable to our pooled MIC distribution. One
possible reason for the discrepancy is the fact that different MIC determination criteria
and incubation times were utilized in this and previous studies (17, 18, 21, 22). SYO MICs
for the QC isolates C. parapsilosis ATCC 22019 (0.06 to 0.25 g/ml) and C. krusei ATCC
6258 (0.06 to 0.5 g/ml) were all within the accepted MIC limits (16). Responses to the
surveys indicated that the SYO MICs from these three laboratories were obtained using
the basic conditions for this broth colorimetric microdilution assay: a color change from
blue to red (instead of growth inhibition) after 48 h of incubation.
Table 3 depicts the ECOFFinder and NRI posaconazole ECVs for 95% and 97.5% of
the population (referred to here as 95% and 97.5% ECVs, respectively), as well as the
single ECVs by the derivatization method, for the different CLSI, EUCAST, Etest, and SYO
MIC distributions for the A. fumigatus SC isolates that were evaluated. The ECOFFinder
and NRI CLSI 97.5% ECVs were 0.5 g/ml when the MICs for the mutant and nonmutant
distributions were merged. However, the CLSI 95% ECOFFinder ECV was 1 dilution
lower (0.25 g/ml) when the MIC distribution for only nonmutant isolates was analyzed.
For the EUCAST and Etest methods, both the 95% and the 97.5% ECOFFinder ECVs were
0.25 g/ml. Therefore, although the inclusion of EUCAST and Etest MICs for the mutants
did not impact the ECV calculation, it impacted the 95% ECOFFinder CLSI result. In our
study, that could be due to the fact that ECOFFinder used more data points, while NRI
utilized only data from the left-hand side of the bell curve and, obviously, the number
of CLSI MICs for mutants was much higher (274 isolates) than that by the EUCAST and
Etest methods (52 and 29 isolates, respectively) (Table 2 and Fig. 1). The smaller number
of mutants was less likely to modify the ECV. For that reason, although the 97.5% ECVs
are the preferred CLSI susceptibility endpoints, the 95% ECOFFinder posaconazole ECV
Espinel-Ingroff et al. Antimicrobial Agents and Chemotherapy
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of 0.25 g/ml could be a more useful endpoint for this species/agent combination.
Given that only 3 of the 8 available SYO MIC distributions were suitable for ECV analysis,
we are proposing a tentative ECOFFinder ECV of 0.06 g/ml, until more SYO posacona-
zole data are gathered. The derivatization method also yielded ECVs of 0.25 g/ml for
the different CLSI, EUCAST, and Etest MIC distributions evaluated and an ECV of 0.06
g/ml for the SYO method. It is noteworthy than an ECV of 0.25 g/ml was the
TABLE 3 ECVs by two analytical techniques for A. fumigatus SC isolates based on MICs
determined by four susceptibility testing methods and originating from 3 and 15
laboratories
Method and distributiona No. of isolates
ECV calculations for
>95/>97.5% of the
population byb:
ECOFFinder NRI
CLSI
Nonmutants 2,223 0.25/0.5 0.5/0.5
Merged data 2,497 0.5/0.5 0.5/0.5
EUCAST
Nonmutants 556 0.25/0.25 0.5/0.5
Merged data 608 0.25/0.25 0.5/0.5
Etest
Nonmutants 1,365 0.25/0.25 0.5/0.5
Merged data 1,394 0.25/0.25 0.5/0.5
SYO, unknown mutant status 381 0.06/0.06 0.12/0.12
aNonmutants, pooled posaconazole MICs for nonmutant isolates; Merged data, aggregated posaconazole
MIC distributions for mutants and nonmutants.
bECVs for 95% and 97.5% of the statistically modeled population by ECOFFinder and NRI calculations and
based on the MICs determined by four susceptibility testing methods (9–11, 13, 15, 16, 25).
FIG 1 Posaconazole MIC distributions for mutant isolates (harboring cyp51A mutations) and nonmutant isolates of the A. fumigatus SC by three
susceptibility testing methods showing the MIC overlap between both MIC distributions. The number of mutant isolates is indicated above the bar for
each MIC.
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endpoint previously proposed for the CLSI method (27) and is advocated by EUCAST
(http://www.eucast.org/ast_of_fungi/).
The most frequent resistance mechanisms in A. fumigatus are modifications in the
azole target enzyme CYP51A (30). The primary role of the ECV is to assist the laboratory
in identifying isolates with phenotypically expressed acquired resistance mechanisms
(6, 7, 9). Given that the ECV does not predict the response to therapy, a “non-WT may
or may not respond to therapy” with the agent being evaluated, in this particular case,
posaconazole (7). For posaconazole, it is clear that some mutations do not affect the
phenotype to the same extent that mutations affect the phenotype for other triazoles;
alternatively, it could be that some mutations might actually be simple (silent) poly-
morphisms (30).
A total of 355 posaconazole MICs for mutant isolates were collected (Table 1 and Fig.
1). The integration of a tandem repeat of 34 bp at the cyp51A promoter, along with a
mutation that produced the replacement of leucine 98 by a histidine at Cyp51Ap
(TR34/L98H), was the most frequent cyp51A mutation observed in the strains included
in this study (68%), followed by the amino substitutions at glycine 54 (G54/E/R/W, 9%)
or at methionine 220 (M220/I/R, 6%). The percentage of TR46/Y121F/T289A mutants
among the three methods was 6%. Although most cyp51A alterations reduce the
phenotype of susceptibility to itraconazole (MICs  8 g/ml), there is some selection/
specificity regarding their effect on the MICs of other triazoles (30). In our study, we
observed an overlap between the MICs for mutant isolates (e.g., isolates linked with the
mutations TR34/L98H, G54E, M220/I/T, G448S, G138C, and others) and those for non-
mutant isolates, that is, MICs of 0.25 g/ml, by the three methods (Tables 1 and 2).
A similar overlap was also reported in other studies not only for posaconazole but also
for voriconazole and, to a lesser extent, for itraconazole by both reference methods
(MIC ranges for cyp51A mutants, 0.06 to 8 g/ml), while the MICs for nonmutants
could have data points above the ECVs for these three agents (0.06 to 8 g/ml) (12,
31–34).
Another reason for proposing the lower ECOFFinder ECV of 0.25 g/ml (which was
also the same with the derivatization method) is that selecting the lower percentage of
the modeled MIC distribution should increase the probability that the ECV would
capture a higher proportion of mutants (9). If the objective is to enhance the detection
of likely cyp51A mutants in particular, then on the basis of the current data, a
CLSI-based ECV of 0.5 g/ml would misclassify 1.8% of nonmutants as non-wild type
and 70.1% of mutants as wild type, whereas 5.8% and 25.2% of isolates, respectively,
would be so classified if the ECV were set at 0.25 g/ml. Lowering the ECV even further
would increase the likelihood of capturing mutants, but at the risk of greatly increasing
the number of wild-type isolates that would be misclassified and subjected to more
complex mutation testing.
In conclusion, our abundant aggregated posaconazole MIC data for A. fumigatus SC
isolates from multiple laboratories and published studies provided a unique opportu-
nity to examine the major overlap in MICs between mutants and nonmutants; it also
demonstrated that there is some degree of interlaboratory variability (e.g., aberrant
distributions, especially among MICs determined by the SYO method). The CLSI 97.5%
ECOFFinder ECV and all NRI endpoints of 0.5 g/ml are too high if the main aim is to
identify isolates with cyp51A mutations regardless of their phenotype. The observed
overlap between MICs for nonmutant and mutant isolates was more evident with the
ECV of 0.5 g/ml (a higher number of posaconazole MICs of 0.5 g/ml for WT
isolates). Therefore, although some overlap is still present, the lower posaconazole
ECOFFinder ECV of 0.25 g/ml for the CLSI, EUCAST, and Etest methods could be more
clinically relevant; this value has been previously proposed for both reference methods.
While we propose a tentative ECOFFinder SYO ECV of 0.06 g/ml, the evaluation of the
SYO MIC distributions from individual laboratories indicated that this method yields less
reliable and much lower MICs than those yielded by the reference methods, possibly
due to the different MIC determination criteria used by the laboratories. At this stage,
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the SYO method should probably not be used for routine testing in the clinical
laboratory for this species/agent combination.
MATERIALS AND METHODS
Isolates. The isolates evaluated were recovered from deep infections at sterile and other sites (mostly
[90%] bronchoalveolar lavage fluid, sputum, and other respiratory-related clinical specimens) at the
following medical centers: VCU Medical Center, Richmond, VA, USA; Mycology Reference Laboratory,
National Centre for Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain; Hôpital
Européen Georges Pompidou, Paris, France; Laboratorio de Micología y Diagnóstico Molecular-Facultad
de Bioquímica y Ciencias Biológicas-Universidad Nacional del Litoral, Consejo Nacional de Investigacio-
nes Científicas y Tecnológicas (CONICET), CCT, Santa Fe, Argentina; Servicio de Microbiología Clínica y
Enfermedades Infecciosas-VIH, Hospital General Universitario Gregorio Marañon, and Instituto de Inves-
tigación Sanitaria Gregorio Marañón, Madrid, Spain; National Mycology Reference Centre, SA Pathology,
Adelaide, Australia; Servicio de Microbiología, Hospital Universitario Central de Asturias, Asturias, Spain;
Institute of Microbiology, Università Cattolica del Sacro Cuore, Rome, Italy; Département de Bactériologie
Virologie Hygiène Mycologie Parasitologie, Créteil, France; Instituto de Medicina Tropical Alexander von
Humboldt-Universidad Peruana Cayetano Heredia, Lima, Peru; Department of Medical Microbiology,
Postgraduate Institute of Medical Education & Research, Chandigarh, India; Department of Medical
Mycology, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India; Klinisk Mikrobiologi, Karo-
linska, Universitetlaboratoriet, Karolinska, Universitetssjukhuset, Stockholm, Sweden; Instituto Nacional
de Enfermedades Infecciosas Dr. C. G. Malbrán, Buenos Aires, Argentina; Universidad Autonóma de
Nuevo León, Monterrey, Nuevo León, México; Mycology Unit Medical School, Universitat Rovira i Virgili,
Reus, Spain; Mycology Reference Laboratory, Public Health England, Bristol, United Kingdom; Public
Health Ontario, Toronto, Ontario, Canada; National Mycology Reference Centre, Division of Hygiene and
Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria; Universidad de Córdoba,
H. G. U. Reina Sofía, Córdoba, Spain; Hospital Valme, Seville, Spain; Universidade Federal de São Paulo,
Laboratório Especial de Micologia, São Paulo, Brazil; University of Iowa College of Medicine, Iowa City, IA,
USA; and the Department of Biomedical Sciences for Health, Università degli Studi di Milano, Milan, Italy.
Posaconazole MICs were collected for a total of 5,276 A. fumigatus complex isolates. The number of
nonmutant MICs in each distribution was as follows: CLSI MICs for 2,223 isolates from 13 participant
laboratories and two previous studies (12, 23), EUCAST MICs for 556 isolates from 5 participant centers
and one prior study (24), Etest MICs for 1,365 isolates from 7 laboratories and one prior study (20), and
SYO MICs for 381 isolates from 3 participant laboratories. In addition, we pooled CLSI, EUCAST, and Etest
MICs for, respectively, 274, 52, and 29 well-characterized mutant isolates (harboring cyp51A gene
mechanisms of resistance, e.g., TR34/L98H, TR46/Y121F/T289A, and others) from both participant labo-
ratories and former studies (12, 20, 23, 24). CLSI posaconazole MICs for 55 A. lentulus and 21 A. udagawae
isolates from three laboratories were also collected. The isolates were identified at each medical center
by conventional and molecular methodologies that included macro- and microscopic morphology,
thermotolerance (incubation at 50°C), MALDI-TOF mass spectrometry, and -tubulin and calmodulin
sequencing (29, 30). Since molecular identification was not performed for all the isolates evaluated in the
present study, we listed the nonmutant isolates in Tables 2 and 3 and Fig. 1 as members of the A.
fumigatus SC. The percentage of A. fumigatus SC isolates versus A. fumigatus sensu stricto isolates is
provided above; most of the mutant isolates were identified in the individual laboratories submitting
data at the level of A. fumigatus sensu stricto; the exceptions were 10 mutants among the Etest data.
Those isolates suspected of harboring cyp51a mutations were screened in the individual laboratories
submitting data using published protocols (30).
At least one of the quality control (QC) isolates, C. parapsilosis ATCC 22019, C. krusei ATCC 6258, or
Paecilomyces variotii ATCC MYA-3630, and/or the reference isolates A. fumigatus ATCC MYA-3626 and A.
flavus ATCC MYA-204304 were evaluated by the different methods in each of the participant laboratories
(10, 11, 14, 16).
Antifungal susceptibility testing. Posaconazole MICs were obtained by the four antifungal suscep-
tibility testing methods by following the specific testing conditions per the answers to the survey
described below (10, 11, 14, 16). The CLSI M38 broth microdilution method was performed with 1 104-
to 5 104-CFU/ml inoculum suspensions and RPMI 1640 medium (0.2% dextrose), and the EUCAST broth
microdilution method was performed with 1  105- to 5  105-CFU/ml inoculum suspensions and RPMI
1640 medium (2% dextrose). MICs were determined by the two reference methods after 48 h of
incubation at 35°C (the MIC was determined from the first well that showed complete inhibition of
growth or that was optically clear). The Etest MICs were determined per the manufacturer’s guidelines,
and the MIC was the lowest drug concentration at which the border of the growth-free elliptical
inhibition intercepted the scale on the antifungal strip after 24 h and, mostly, 48 h of incubation. The SYO
MICs were determined by the manufacturer’s guidelines, and the SYO MIC was the concentration in the
first blue well after 48 h. Other specific details, including data for the QC isolates, were discussed above.
Definitions. The following definitions have been widely described elsewhere as well as above (6, 7,
28). The ECV is the highest MIC/MEC distribution of the WT population and should be established by
using reliable MIC/MEC distributions from at least three laboratories. A non-WT organism usually shows
reduced susceptibility to the agent being evaluated compared to that of the WT (no phenotypic
resistance) population. In addition to MIC distributions, the ECV calculation takes into account each
laboratory distribution mode, the inherent variability of the test (usually within 1 doubling dilution), and
the fact that the ECV should encompass 95 to 97% of isolates. Most published ECVs are based on
reference MIC distributions, and ECVs based on other methods could be different. We used the same
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criteria and requirements for establishing proposed CLSI, EUCAST, Etest, and SYO method-dependent
ECVs.
Surveys. As mentioned above, to investigate the possible causes of modal variability, the 26
participant laboratories providing the different sets of MIC data (Table 2) responded to specific param-
eters for each method. Overall the questions were as follows: (i) was the medium formulation as indicated
for each method, (ii) were the MICs always read at the optimal incubation and time for each method, and
(iii) what was the growth inhibition criteria used to determine the MICs for each method?
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